Mer­ck, Am­gen back a $30M play for Ri­bometrix — one of the up­starts mak­ing its mark in drug­ging RNA

The idea that you can drug RNA has at­tract­ed a va­ri­ety of biotech star­tups in­ter­est­ed in pi­o­neer­ing a new tech­nol­o­gy. And one of those biotechs look­ing to break new ground in the field just scooped up a $30 mil­lion round.

The Durham, NC-based biotech Ri­bometrix is the brain­child of Kevin Weeks, the UNC in­ves­ti­ga­tor who hatched the sci­en­tif­ic ideas that would go on to cre­ate the plat­form at Ri­bometrix.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.